2023-05-10 16:12:29 ET
- AcelRx Pharmaceuticals press release ( NASDAQ: ACRX ): Q1 GAAP EPS of -$0.75 beats by $0.04 .
- The cash and cash equivalents balance was $13.4 million as of March 31, 2023.
- Combined R&D and SG&A expenses for the first quarter of 2023 totaled $5.3 million compared to $4.9 million for the first quarter of 2022.
- Excluding non-cash stock-based compensation expense, these amounts were $4.8 million for the first quarter of 2023, compared to $4.3 million for the first quarter of 2022.
For further details see:
AcelRx Pharmaceuticals GAAP EPS of -$0.75 beats by $0.04